TNF and Respiratory tract infection: A meta-estimate from phase 3 placebo-controlled clinical trials of anti-TNF-α in psoriasis found no evidence of an increased risk of respiratory tract infection (RTI) (OR 1.08; 95% CI 0.84–1.38) [29].